Bioatla, inc. BCAB.US Overview
BCAB AI Analysis & Strategy
Analysis Conclusion
The stock has a lower value rating; if aiming for value investing, existing long-term positions might require gradual reduction.
BCAB Current Performance
-1.39%
Bioatla, inc.
0.71%
Avg of Sector
-0.11%
S&P500
BCAB Key Information
BCAB Financial Forecast
Unit : USD
BCAB Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | -0.63 | - | -12.5% | 250K | - | -94.6% | - |
| 2021Q2 | -0.68 | - | -26.1% | 150K | - | -96.7% | -12,152.4% |
| 2021Q1 | -0.9 | - | 60.7% | 250K | - | 2.8% | - |
BCAB Profile
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.